Immune-based therapies for childhood cancer

Crystal L. Mackall, Melinda S. Merchant, Terry J. Fry

Research output: Contribution to journalArticle

Abstract

After decades of research, immunotherapies for cancer are demonstrating increasing success. These agents can amplify existent antitumour immunity or induce durable antitumour immune responses in a wide array of cancers. The spectrum of immunotherapeutics is broad, spanning monoclonal antibodies and their derivatives, tumour vaccines, and adoptive therapies using T cells and natural killer cells. Only a small number of immunotherapies have been tested in paediatric cancers, but impressive antitumour effects have already been observed. Mononclonal antibodies targeting GD2 that induce antibody-dependent cell-mediated cytotoxicity improve survival in high-risk neuroblastoma. Bi-specific monoclonal antibodies that simultaneously target CD19 and activate T cells can induce remission in acute B-cell lymphoblastic leukaemia (B-ALL) and adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors targeting CD19 induce impressive responses in B-ALL. Efforts are underway to generate and test new immunotherapies in a wider array of paediatric cancers. Major challenges include a need to identify immunotherapy targets on the most lethal childhood cancers, to expand availability of technology-intense platforms, such as adoptive cell therapy, to optimize management of novel toxicities associated with this new class of cancer therapies and to determine how best to incorporate these therapies into standard treatment paradigms.

Original languageEnglish (US)
Pages (from-to)693-703
Number of pages11
JournalNature Reviews Clinical Oncology
Volume11
Issue number12
DOIs
StatePublished - Dec 11 2014
Externally publishedYes

Fingerprint

Immunotherapy
Neoplasms
T-Lymphocytes
Therapeutics
Monoclonal Antibodies
B-Cell Leukemia
Pediatrics
Antibody-Dependent Cell Cytotoxicity
Adoptive Immunotherapy
Active Immunotherapy
Cancer Vaccines
Antigen Receptors
Cell- and Tissue-Based Therapy
Neuroblastoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Natural Killer Cells
Immunity
Technology
Antibodies
Research

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Immune-based therapies for childhood cancer. / Mackall, Crystal L.; Merchant, Melinda S.; Fry, Terry J.

In: Nature Reviews Clinical Oncology, Vol. 11, No. 12, 11.12.2014, p. 693-703.

Research output: Contribution to journalArticle

Mackall, CL, Merchant, MS & Fry, TJ 2014, 'Immune-based therapies for childhood cancer', Nature Reviews Clinical Oncology, vol. 11, no. 12, pp. 693-703. https://doi.org/10.1038/nrclinonc.2014.177
Mackall, Crystal L. ; Merchant, Melinda S. ; Fry, Terry J. / Immune-based therapies for childhood cancer. In: Nature Reviews Clinical Oncology. 2014 ; Vol. 11, No. 12. pp. 693-703.
@article{a460d2b617404181a400b0c32e9e0fe3,
title = "Immune-based therapies for childhood cancer",
abstract = "After decades of research, immunotherapies for cancer are demonstrating increasing success. These agents can amplify existent antitumour immunity or induce durable antitumour immune responses in a wide array of cancers. The spectrum of immunotherapeutics is broad, spanning monoclonal antibodies and their derivatives, tumour vaccines, and adoptive therapies using T cells and natural killer cells. Only a small number of immunotherapies have been tested in paediatric cancers, but impressive antitumour effects have already been observed. Mononclonal antibodies targeting GD2 that induce antibody-dependent cell-mediated cytotoxicity improve survival in high-risk neuroblastoma. Bi-specific monoclonal antibodies that simultaneously target CD19 and activate T cells can induce remission in acute B-cell lymphoblastic leukaemia (B-ALL) and adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors targeting CD19 induce impressive responses in B-ALL. Efforts are underway to generate and test new immunotherapies in a wider array of paediatric cancers. Major challenges include a need to identify immunotherapy targets on the most lethal childhood cancers, to expand availability of technology-intense platforms, such as adoptive cell therapy, to optimize management of novel toxicities associated with this new class of cancer therapies and to determine how best to incorporate these therapies into standard treatment paradigms.",
author = "Mackall, {Crystal L.} and Merchant, {Melinda S.} and Fry, {Terry J.}",
year = "2014",
month = "12",
day = "11",
doi = "10.1038/nrclinonc.2014.177",
language = "English (US)",
volume = "11",
pages = "693--703",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Immune-based therapies for childhood cancer

AU - Mackall, Crystal L.

AU - Merchant, Melinda S.

AU - Fry, Terry J.

PY - 2014/12/11

Y1 - 2014/12/11

N2 - After decades of research, immunotherapies for cancer are demonstrating increasing success. These agents can amplify existent antitumour immunity or induce durable antitumour immune responses in a wide array of cancers. The spectrum of immunotherapeutics is broad, spanning monoclonal antibodies and their derivatives, tumour vaccines, and adoptive therapies using T cells and natural killer cells. Only a small number of immunotherapies have been tested in paediatric cancers, but impressive antitumour effects have already been observed. Mononclonal antibodies targeting GD2 that induce antibody-dependent cell-mediated cytotoxicity improve survival in high-risk neuroblastoma. Bi-specific monoclonal antibodies that simultaneously target CD19 and activate T cells can induce remission in acute B-cell lymphoblastic leukaemia (B-ALL) and adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors targeting CD19 induce impressive responses in B-ALL. Efforts are underway to generate and test new immunotherapies in a wider array of paediatric cancers. Major challenges include a need to identify immunotherapy targets on the most lethal childhood cancers, to expand availability of technology-intense platforms, such as adoptive cell therapy, to optimize management of novel toxicities associated with this new class of cancer therapies and to determine how best to incorporate these therapies into standard treatment paradigms.

AB - After decades of research, immunotherapies for cancer are demonstrating increasing success. These agents can amplify existent antitumour immunity or induce durable antitumour immune responses in a wide array of cancers. The spectrum of immunotherapeutics is broad, spanning monoclonal antibodies and their derivatives, tumour vaccines, and adoptive therapies using T cells and natural killer cells. Only a small number of immunotherapies have been tested in paediatric cancers, but impressive antitumour effects have already been observed. Mononclonal antibodies targeting GD2 that induce antibody-dependent cell-mediated cytotoxicity improve survival in high-risk neuroblastoma. Bi-specific monoclonal antibodies that simultaneously target CD19 and activate T cells can induce remission in acute B-cell lymphoblastic leukaemia (B-ALL) and adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors targeting CD19 induce impressive responses in B-ALL. Efforts are underway to generate and test new immunotherapies in a wider array of paediatric cancers. Major challenges include a need to identify immunotherapy targets on the most lethal childhood cancers, to expand availability of technology-intense platforms, such as adoptive cell therapy, to optimize management of novel toxicities associated with this new class of cancer therapies and to determine how best to incorporate these therapies into standard treatment paradigms.

UR - http://www.scopus.com/inward/record.url?scp=84927176568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927176568&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2014.177

DO - 10.1038/nrclinonc.2014.177

M3 - Article

C2 - 25348789

AN - SCOPUS:84927176568

VL - 11

SP - 693

EP - 703

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 12

ER -